Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
RBN-2397 is a small molecule inhibitor that targets PARP7, potentially inducing type I interferon signaling, which may lead to an immune response and tumor regression (PMID: 34375612).
|CAS Registry Number||2381037-82-5|
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|Pembrolizumab + RBN-2397||Pembrolizumab RBN-2397||0||1|